A new COVID-19 medication so good that it allowed scientists to stop trials early!

Mohamad Ali Salloum, PharmD • April 13, 2022

Share

  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button

The molecule is called “Sabizabulin”, and the manufacturer is called “Veru”, an oncology biopharmaceutical company that is based in USA.


This medication was being tested in moderate and severe COVID-19 cases, and it worked! The results show that it has the potential to cut the virus’s mortality rate by more than 50%.


Note that the Mortality rate is a measure of the number of deaths in a particular population per unit of time.


Usually in clinical trials, the study team perform an interim analysis, which is a statistical analysis done on the data at some point during the study to see if they continue with the trial or put it down. If the results are positive, the clinical trial continues recruiting more patients to reach its target. If the results are negative, the clinical trial may be terminated if it is clear that the study drug is not superior to the standard therapy/placebo.


This study was randomized, double-blinded, placebo-controlled phase 3 Covid-19 clinical trial. Patients in both treatment groups were allowed to receive standard of care including remdesivir, dexamethasone, anti-IL6 receptor antibodies, and JAK inhibitors. Placebo group (n=52) had a 45% mortality rate compared to the sabizabulin-treated group (n=98) which had a 20% mortality rate. The interim analysis results were so good that it was unethical to continue giving the patients a placebo.


An Independent Data Management Committee (IDMC) recommended the study to be stopped early due to overwhelming evidence of efficacy. The article published stated that Sabizabulin showed statistically and clinically meaningful 55% reduction in deaths compared to Placebo in Moderate-Severe hospitalized patients (p=0.0029).


Regarding its safety profile, the medication was well tolerated, and no safety concerns were identified.


The next steps is that Veru will meet with FDA to seek Emergency Use Authorization. This means that the medication may be available in the market in the next few months.


Gary Barnette, PhD, Chief Scientific Officer of Very has stated that “What makes these findings more relevant is that the pharmacological activity of sabizabulin is independent of COVID-19 variant type.”

As a summary:

Drug Class Bis-Indole
Mechanism of Action It binds to the "Colchicine binding site" of Alpha and Beta tubulin and inhibits tubulin polymerization at low nanomolar concentrations.
Used as Anti-Viral, Anti-Inflammatory
Route of Administration Oral
Dose 9 mg
Safety Profile Well tolerated

List of Services

    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button

    ABOUT THE AUTHOR

    Mohamad-Ali Salloum, PharmD

    Mohamad Ali Salloum LinkedIn Profile

    Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.

    Share

    Recent articles:

    By Mohamad-Ali Salloum, PharmD June 12, 2026
    The deadly combo of Alcohol and Paracetamol!!
    By Mohamad-Ali Salloum, PharmD June 10, 2026
    References: Han A, Kim TH. Effects of self-compassion interventions on reducing depressive symptoms, anxiety, and stress: a meta-analysis. Mindfulness (N Y). 2023;[Epub ahead of print]. [pmc.ncbi.nlm.nih.gov] Li X, Malli MA, Cosco TD, Zhou G. The relationship between self-compassion and resilience in the general population: protocol for a systematic review and meta-analysis. JMIR Res Protoc. 2024;13:e60154. [researchpr...tocols.org] Buenrostro-Jáuregui MH, Muñoz-Sánchez S, Rojas-Hernández J, Alonso-Orozco AI, Vega-Flores G, Tapia-de-Jesús A, et al. A comprehensive overview of stress, resilience, and neuroplasticity mechanisms. Int J Mol Sci. 2025;26(7):3028. [mdpi.com] Pickersgill JW, Turco CV, Ramdeo K, Rehsi RS, Foglia SD, Nelson AJ. The combined influences of exercise, diet and sleep on neuroplasticity. Front Psychol. 2022;13:831819. [frontiersin.org] Ren B, Yuan Q, Cha S, Liu S, Zhang J, Guo G. Maladaptive neuroplasticity under stress: insights into neuronal and synaptic changes in the prefrontal cortex. Mol Neurobiol. 2025;[Epub ahead of print]. [link.springer.com] Blum K. The impact of chronic stress on brain function and structure. Neurosci Psychiatry Open Access. 2024;7(5). [openaccess...urnals.com] Wang X, Feng Z. A narrative review of empirical literature of behavioral activation treatment for depression. Front Psychiatry 2022;13:845138. [frontiersin.org]
    By Mohamad-Ali Salloum, PharmD June 8, 2026
    References: Maloney D. The Balance Between Self-Discipline and Self-Compassion. 2026. 3 Hominick G. Self-Compassion vs. Self-Criticism: Why Beating Yourself Up Doesn’t Work. Aletheia Counseling. 2026 Jan 16. Eyal N. Studies Show Self-Compassion Is the Motivator You’re Missing. Psychology Today. 2024 Apr 23. Hollinshead J. Self-Discipline vs. Self-Compassion. Peak Resilience. 2026.
    By Mohamad-Ali Salloum, PharmD June 4, 2026
    References: Quattash MS. The Depleted Mind: The Science of Decision Fatigue and Ego Depletion. Global Council for Behavioral Science. 2025. Available from: https://gc-bs.org/articles/the-depleted-mind-the-science-of-decision-fatigue-and-ego-depletion/ 5 Choudhury NA, Saravanan P. An integrative review on the causes and effects of decision fatigue. Front Cognit. 2026;4:1719312. Available from: https://www.frontiersin.org/journals/cognition/articles/10.3389/fcogn.2025.1719312/full 4 Schweitzer DR, Baumeister RF, Laakso EL, Ting J. Self-control, limited willpower and decision fatigue in healthcare settings. Intern Med J. 2023. Available from: https://onlinelibrary.wiley.com/doi/pdf/10.1111/imj.16121 3 Ordali E, Pietrini P. Mental fatigue leads to loss of self-control and poor decision-making. Coverage in The Brighter Side of News. 2024. Available from: https://www.thebrighterside.news/post/mental-fatigue-leads-to-loss-of-self-control-and-poor-decision-making/ 2 Woodley BioReg. Decision Fatigue and Cognitive Load: A Scientific Perspective. Woodley BioReg. 2026. Available from: https://www.woodleybioreg.com/decision-fatigue-and-cognitive-load-a-scientific-perspective/ 1 Keller AJ. Decision Fatigue: What It Is and How It Affects Your Brain. Neurosity Guide. 2026. Available from: https://neurosity.co/guides/decision-fatigue-brain
    By Mohamad-Ali Salloum, PharmD June 2, 2026
    Understand the key difference between cravings and temptations, and learn how your body and mind influence your choices with simple, practical insights to improve self-control.
    By Mohamad-Ali Salloum, PharmD May 31, 2026
    Learn how to control your actions during intense emotions using science-backed techniques. Discover practical strategies like pausing, reframing, and grounding to stay calm, think clearly, and respond wisely in stressful situations.
    By Mohamad-Ali Salloum, PharmD May 29, 2026
    Lose weight while working!
    By Mohamad-Ali Salloum, PharmD May 27, 2026
    How are we using old software in a modern hardware?
    By Mohamad-Ali Salloum, PharmD May 26, 2026
    Understand why avoiding what makes you anxious brings short-term relief but worsens anxiety over time. Learn the science behind avoidance and effective ways to break the cycle.
    By Mohamad-Ali Salloum, PharmD May 25, 2026
    Learn how sleep affects productivity, cognitive function, memory, focus, and emotional well-being. A science-based guide to optimizing your performance through better sleep.
    More Posts